期刊文献+

干扰素聚乙二醇修饰的研究进展 被引量:1

Advances in research on PEGylation of interferon
原文传递
导出
摘要 干扰素(Interferon,IFN)是一类具有抗病毒、免疫调节、抑制细胞增殖等多种生物活性的细胞因子,而体内循环半衰期短限制了其在临床上的应用。聚乙二醇(Polyethylene glycol,PEG)修饰可以有效地改善干扰素的理化性质和生物学特性,延长体内循环半衰期。本文综述了聚乙二醇修饰干扰素的研究进展,着重介绍了聚乙二醇修饰化学的发展,α、β、γ干扰素各自不同的聚乙二醇化学修饰方法,并对聚乙二醇化干扰素的发展趋势进行了展望。 Interferon (IFN) contains a family of cytokines that display a wide range of antiviral, immunomodulatory, and antiproliferative activities, but unfortunately the short circulating half-life limits their clinical applications. PEGylation may improve the physicochemical and biological characteristics, and extend the plasma circulating half-life of IFN. Recent advances in PEGylation of IFNs were reviewed in this paper, while the development of PEGylation of IFNs α, β, and γwere particularly introduced. Finally, the future trends and prospects in PEGylation of IFNs were predicted.
作者 郑博 王劲峰
出处 《中国生物制品学杂志》 CAS CSCD 2013年第2期292-296,共5页 Chinese Journal of Biologicals
关键词 干扰素 聚乙二醇类 聚乙二醇修饰 聚乙二醇化干扰素 Interferon (IFN) Polyethylene glycols PEGylation PEGylated interferon (PEG-IFN)
  • 相关文献

参考文献26

  • 1Meager A. The interferons: Past, present and future [J ]. Dig Liver Dis Suppl, 2009, 3 ( 1 ): 3-8.
  • 2Miller CH. Maher SG, Young HA. Clinical use of interferon- gamma [J]. Ann N Y Acad Sci, 2009, 1182 ( 1 ): 69-79.
  • 3Pasut G, Veronese FM. State of the art in PEGylation: the great versatility achieved after forty years of research [J ]. J Control Release, 2012, 161 (2): 461-472.
  • 4董惠钧,姜俊云,郑立军,庞俊星.蛋白药物聚乙二醇修饰技术研究进展[J].中国生化药物杂志,2009,30(3):199-203. 被引量:12
  • 5Veronese FM, Mero A. The impact of PEGylation on biological therapies [J]. BioDrugs, 2008, 22 (5): 315-329.
  • 6Pasut G, Veronese FM. PEG conjugates in clinical development or use as anticancer agents: an overview [J].Adv Drag Deliv Rev, 2009, 61 ( 13 ): 1177-1188.
  • 7Jevsevar S, Kunstelj M, Porekar VG. PEGylation of therapeutic proteins [J]. Biotechnol J, 2010. 5 (1): 113-128.
  • 8Monkarsh SP, Ma YM. Aglione A, et al. Positional isomers of monopegylated interferon α-2a: Isolation, characterization, and biological activity [J ]. Anal Biochem. 1997, 247 (2): 434-440.
  • 9Basu A, Yang K, Wang ML, et al. Struture-function engineering of interferon-β-1b for improving stability, solubility, potency. immunogenicity, and pharmacokinetic propertics by site-selective mono-PEGylation [ J ]. Bioconjug Chem, 2006. 17 ( 3 ): 618-630.
  • 10杨宇峰,黄静,徐帆洪,吴腾捷,吴自荣,楼觉人.聚乙二醇修饰重组人干扰素-α1b条件的优化[J].中国生物制品学杂志,2008,21(4):329-332. 被引量:5

二级参考文献223

  • 1胡永祥,牛津梁,张文博,高林.聚乙二醇修饰药物技术的研究进展[J].中国生化药物杂志,2004,25(6):369-373. 被引量:12
  • 2Abuchowski A,Van Es T,Palczuk N C,et al.Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol[J].J Biol Chem,1977,252 (11):3578-3581.
  • 3Davis F F.The origin of pegnology[J].Adv Drug Delivery Rev,2002,54(4):457-458.
  • 4Ryan S M,Mantovani G,Wang X,et al.Advances in PEGylation of important biotech molecules:delivery aspects[J].Expert Opin Drug Deliv,2008,5(4):371-383.
  • 5Hamidi M,Azadi A,Rafiei P.Pharmacokinetic consequences of pegylation[J].Drug Deliv,2006,13(6):399-409.
  • 6Na D H,Lee K C,DeLuca P P.PEGylation of octreotide:Ⅱ.Effect of N-terminal mono-PEGylation on biological activity and pharmacokinetics[J].Pharm Res,2005,22(5):743-749.
  • 7Meng F,Manjula B N,Smith P K,et al.PEGylation of human serum albumin:reaction of PEG-phenyl-isothiocyanate with protein[J].Bioconjug Chem,2008,19(7):1352-1360.
  • 8Lecolley F,Tao L,Mantovani G,et al.A new approach to bioconjugates for proteins and peptides ("pegylation") utilising living radical polymerization[J].Chem Commun (Camb),2004,18:2026-2027.
  • 9Veronese F M.Peptide and protein PEGylation:a review of problems and solutions[J].Biomaterials,2001,22(5):405-417.
  • 10Park E J,Na D H.Optimization of oetreotide PEGylation by monitoring with fast reversed-phase high-performance liquid chromatography[J].Anal Biochem,2008,380(1):140-142.

共引文献56

同被引文献4

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部